0 BioMalPar XV: Biology and Pathology of the Malaria Parasite
B. Joanne Power gives us a summary of the conference highlights from BioMalPar XV, including new strategies for vector control and new insights into the malaria parasite.
Browsing: Disease Area > Viral
0 Polio, picornaviruses and publicizing science – an interview with Vincent Racaniello
In this interview we speak to Vincent Racaniello, Professor of Microbiology & Immunology, about his work on polio, picornaviruses and publicizing science through blogs and podcasts.
1 Two Ebola treatments prove effective in DRC outbreak
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
0 CNS infections: interferon gamma could play a role in blood–brain barrier breakdown
A new study has implicated the cytokine interferon gamma as a major contributor of blood–brain barrier breakdown in central nervous system infections.
0 Respiratory syncytial virus: experimental structure-based vaccine candidate shows promise in Phase I trial
Researchers from the University of Texas at Austin have passed an experimental RSV vaccine through Phase I human clinical trial with promising results.
0 MERS vaccine safe and immunogenic in first-in-human trial
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
0 IAS 2019: highlights and headlines
Find out more about the headlines from the 10th International AIDS Society Conference on HIV Science (IAS 2019) in our round-up of conference news.
0 HIV linked to cognitive defects in individuals, despite antiretroviral therapy
Despite long-term antiretroviral therapy, cerebrospinal HIV reservoirs have been identified in individuals living with the virus and linked with a higher rate of cognitive defects.
0 Modulating arbovirus infection via mosquito saliva – an interview with Daniella Lefteri
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
0 CRISPR and long-acting therapies eliminate HIV DNA from the genome in animal models
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
